Rate My Professor Paul King

Professor Paul King, MD, PhD, is an Adjunct Associate Professor and Senior Lecturer in the Faculty of Medicine, Nursing and Health Sciences at Monash University. He serves as Adjunct Clinical Professor in the Department of Medicine at Monash Health and as Head of the Inflammatory Respiratory Disease Research Group in the School of Clinical Sciences at Monash Health. As a respiratory and sleep physician at Monash Lung and Sleep, Monash Medical Centre, Professor King integrates clinical practice with research focused on chronic inflammatory lung conditions.

Throughout his career at Monash University and Monash Health, Professor King has made substantial contributions to respiratory medicine, particularly investigating the immunological mechanisms underlying diseases such as chronic obstructive pulmonary disease (COPD), bronchiectasis, and cystic fibrosis. His studies examine bacterial roles in lung pathology, including nontypeable Haemophilus influenzae-induced inflammation and T-cell responses in chronic infections. He has produced over 79 research outputs, encompassing 60 journal articles, review articles, book chapters, and letters. Key publications include "Pirfenidone Mitigates Transforming Growth Factor-β-induced Inflammation after Viral Infection" (Thomas et al., 2025, American Journal of Respiratory Cell and Molecular Biology), "Current physiotherapy practice for adults with bronchiectasis: Data from the Australian bronchiectasis registry" (Webb et al., 2024, Respiratory Medicine), "Bacteria in COPD; their potential role and treatment" (King et al., 2013), "Nontypeable Haemophilus influenzae Induces Sustained Lung Inflammation" (King et al., 2015, PLOS ONE), "Lung T-cell responses to nontypeable Haemophilus influenzae in human COPD" (King et al., 2013, Journal of Allergy and Clinical Immunology), and "Outcome in Adult Bronchiectasis" (King et al., 2005). Professor King participates in multi-center initiatives like the Australian Bronchiectasis Registry and serves on the editorial board of Clinical and Translational Discovery.